#USA #New York #Class Action #Securities Fraud #Novo Nordisk

Investors Invited to Join Class Action Against Novo Nordisk A/S

Levi & Korsinsky, LLP has issued an important alert for individuals who have incurred losses while investing in Novo Nordisk A/S (NYSE: NVO). This notice pertains to a class action securities lawsuit that could provide monetary recovery for those affected during a specific time frame. The lawsuit stems from allegations of securities fraud that were purportedly committed by the company between May 7, 2025, and July 28, 2025.

Class Definition and Case Details

The class action aims to seek justice for investors who faced negatively influenced decisions due to misleading statements and material omissions surrounding Novo Nordisk’s market potential. According to the details of the complaint, the company made overly optimistic public statements about its growth while hiding crucial adverse information. This included the fact that Novo’s predictions regarding its market prospects were vastly overstated, particularly related to the compounded GLP-1 market and the likelihood of patients switching to its branded therapies.

In a startling announcement on July 29, 2025, Novo Nordisk revised its sales and profit forecasts downward. The company cited “lowered growth expectations for the second half of 2025” as a primary reason affecting both of its leading products, Wegovy and Ozempic. Indeed, the announcement noted the persistent use of compounded GLP-1s, slower than anticipated market expansion, and increased competition as contributing factors. Following this news, Novo's common stock suffered a significant jolt, plummeting from $69.00 per share on July 28 to $53.94 per share the following day, marking a rapid decline of approximately 21.83% in just 24 hours.

What's Next for Affected Investors?

Those investors who believe they have suffered losses due to the fraudulent activities of Novo Nordisk must take action quickly. The court has set a deadline of September 30, 2025, for individuals to request consideration as lead plaintiffs in this significant case. It is important to note that participating in the lawsuit as a class member does not mandate serving as a lead plaintiff, and victims may still be eligible for compensation without upfront costs.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built an impressive track record over the past two decades, successfully recovering hundreds of millions of dollars for shareholders affected by corporate malfeasance. Their experienced team specializes in complex securities litigation and maintains a dedicated staff of over 70 professionals ready to assist clients through each step of the litigation process.

The firm has consistently been recognized in the Top 50 Report by ISS Securities Class Action Services for seven consecutive years, highlighting their expertise and reputation in the field of securities litigation in the United States.

Contact Information

Investors who feel they might qualify for this lawsuit or seek additional details can reach out directly to:

• - Joseph E. Levi, Esq.
• - Ed Korsinsky, Esq.
• - Levi & Korsinsky, LLP
• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Telephone: (212) 363-7500

For more information, interested parties can also visit the official website for submission details about the ongoing class action proceedings.

In the wake of significant financial loss, timely action is crucial for investors impacted by the alleged misconduct associated with Novo Nordisk A/S. Whether you lost money during the specified period or have general inquiries about the case, do not hesitate to reach out to the experts at Levi & Korsinsky today.